PDF herunterladen
Exp Clin Endocrinol Diabetes 2016; 124(06): 372-379
DOI: 10.1055/s-0042-100911
Article
© Georg Thieme Verlag KG Stuttgart · New York

Clinical and Pathological Characteristics of Hypertensive and Normotensive Adrenal Pheochromocytomas

Y. Lu   *
1   Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
,
P. Li   *
1   Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
,
W. Gan   *
2   Department of Urology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
,
X. Zhao
2   Department of Urology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
,
S. Shen
1   Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
,
W. Feng
1   Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
,
Q. Xu
1   Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
,
Y. Bi
1   Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
,
H. Guo
2   Department of Urology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
,
D. Zhu
1   Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 01. Dezember 2015
revised 31. Dezember 2015

accepted 15. Januar 2016

Publikationsdatum:
24. Mai 2016 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Introduction: Pheochromocytoma/Paraganglioma (PPGL) present with an extremely variable clinical picture which ranges from dramatic, to mild, to silent, depending on tumor attitude to release catecholamines. Hypertension is the hallmark of these tumors but is not always present. Distinct differences of clinical manifestations exist in hypertensive pheochromocytomas (HPs) and normotensive pheochromocytomas (NPs), however the comparative analysis is lacking.

Methods: The objective was to assess the clinical symptoms, hemodynamics, metabolism, radiological and histological features of patients with HPs and NPs. This study included 104 pheochromocytoma patients who were categorized into HPs (n=69) and NPs (n=35) groups. All clinical records were reviewed. Tumor samples were examined to determine the Adrenal Gland Scale Score and were available for measurement of gene transcriptions. Biochemical examinations of 95 subjects with primary hypertension (PH) were recorded for comparative study.

Results: Patients with NPs showed lower proportion of clinical triad, inapparent metabolic disorders and lower urinary catecholamine levels than HPs, but higher than PH. Tumor weight positively correlated with 24 h urinary norepinephrine level in patients with HPs (P=0.028), and tumor diameter negatively correlated with phenylethanolamine-N-methyltransferase (PNMT) immunohistochemistry (P=0.011) in NPs but not in HPs. The Adrenal Gland Scale Score of NPs group was similar to that of HPs group. The positive percentage of epinephrine type (E-type) of catecholamine in HPs group was higher than that in the NPs. The transcript gene levels of PNMT, secretogranin II (SGII) and neuropeptide Y (NPY) from tissue samples were significantly lower in NPs than in HPs (PPNMT=0.038, PSGII=0.040, PNPY=0.032), while vesicular monoamine transporter 1 (VMAT1) had no difference between HPs and NPs (PVMAT1=0.053).

Conclusion: HPs and NPs have distinct differences in clinical, biochemical and pathological phenotypes, which are closely related with productions involved in tumor occurrence and development.

Key words

adrenal medulla - catecholamine - hypertension - metabolism - pheochromocytoma

* Yao Lu, Ping Li, and Weidong Gan contributed equally to the paper.


Supplementary Material

 

  • References

  • 1 Kantorovich V, Pacak K. Pheochromocytoma and paraganglioma. Progress in brain research 2010; 182: 343-373
    PubMedSuche in Google Scholar
  • 2 Zuber SM, Kantorovich V, Pacak K. Hypertension in pheochromocytoma: characteristics and treatment. Endocrinol Metab Clin North Am 2011; 40: 295-311 vii
    CrossrefPubMedSuche in Google Scholar
  • 3 Guerrero MA, Schreinemakers JM, Vriens MR et al. Clinical spectrum of pheochromocytoma. Journal of the American College of Surgeons 2009; 209: 727-732
    CrossrefPubMedSuche in Google Scholar
  • 4 Pacak K. Phaeochromocytoma: a catecholamine and oxidative stress disorder. Endocr Regul 2011; 45: 65-90
    CrossrefPubMedSuche in Google Scholar
  • 5 Kopetschke R, Slisko M, Kilisli A et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. European journal of endocrinology / European Federation of Endocrine Societies 2009; 161: 355-361
    CrossrefPubMedSuche in Google Scholar
  • 6 Noshiro T, Shimizu K, Watanabe T et al. Changes in clinical features and long-term prognosis in patients with pheochromocytoma. American journal of hypertension 2000; 13: 35-43
    CrossrefPubMedSuche in Google Scholar
  • 7 Amar L, Servais A, Gimenez-Roqueplo AP et al Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. The Journal of clinical endocrinology and metabolism 2005; 90: 2110-2116
    CrossrefPubMedSuche in Google Scholar
  • 8 Mannelli M, Ianni L, Cilotti A et al. Pheochromocytoma in Italy: a multicentric retrospective study. European journal of endocrinology/European Federation of Endocrine Societies 1999; 141: 619-624
    CrossrefPubMedSuche in Google Scholar
  • 9 Lee JA, Zarnegar R, Shen WT et al. Adrenal incidentaloma, borderline elevations of urine or plasma metanephrine levels, and the “subclinical” pheochromocytoma. Arch Surg 2007; 142: 870-873 discussion 873–874
    CrossrefPubMedSuche in Google Scholar
  • 10 Haissaguerre M, Courel M, Caron P et al. Normotensive incidentally discovered pheochromocytomas display specific biochemical, cellular, and molecular characteristics. The Journal of clinical endocrinology and metabolism 2013; 98: 4346-4354
    CrossrefPubMedSuche in Google Scholar
  • 11 Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of hypertension 2013; 31: 1281-1357
    CrossrefPubMedSuche in Google Scholar
  • 12 Force IDFCGT . Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabetic medicine: a journal of the British Diabetic Association 2006; 23: 579-593
    CrossrefPubMedSuche in Google Scholar
  • 13 Manger WM. An overview of pheochromocytoma: history, current concepts, vagaries, and diagnostic challenges. Annals of the New York Academy of Sciences 2006; 1073: 1-20
    CrossrefPubMedSuche in Google Scholar
  • 14 Manger WM, Eisenhofer G. Pheochromocytoma: diagnosis and management update. Curr Hypertens Rep 2004; 6: 477-484
    CrossrefPubMedSuche in Google Scholar
  • 15 Bittar DA. Innovar-induced hypertensive crises in patients with pheochromocytoma. Anesthesiology 1979; 50: 366-369
    CrossrefPubMedSuche in Google Scholar
  • 16 Kimura N, Watanabe T, Noshiro T et al. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocrine pathology 2005; 16: 23-32
    CrossrefPubMedSuche in Google Scholar
  • 17 Eiden LE, Schafer MK, Weihe E et al. The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine. Pflugers Archiv: European journal of physiology 2004; 447: 636-640
    PubMedSuche in Google Scholar
  • 18 Omura M, Saito J, Yamaguchi K et al. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertension research: official journal of the Japanese Society of Hypertension 2004; 27: 193-202
    CrossrefPubMedSuche in Google Scholar
  • 19 Zelinka T, Eisenhofer G, Pacak K. Pheochromocytoma as a catecholamine producing tumor: implications for clinical practice. Stress 2007; 10: 195-203
    CrossrefPubMedSuche in Google Scholar
  • 20 Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocrine reviews 2003; 24: 539-553
    CrossrefPubMedSuche in Google Scholar
  • 21 Zhu Y, He HC, Su TW et al. Selective a1-adrenoceptor antagonist (controlled release tablets) in preoperative management of pheochromocytoma. Endocrine connections. 2010 38. 254-259
    PubMedSuche in Google Scholar
  • 22 Fung MM, Viveros OH, O’Connor DT. Diseases of the adrenal medulla. Acta Physiol (Oxf) 2008; 192: 325-335
    PubMedSuche in Google Scholar
  • 23 Manger WM. The protean manifestations of pheochromocytoma. Hormone and metabolic research 2009; 41: 658-663
    Thieme ConnectPubMedSuche in Google Scholar
  • 24 Ito Y, Fujimoto Y, Obara T. The role of epinephrine, norepinephrine, and dopamine in blood pressure disturbances in patients with pheochromocytoma. World journal of surgery 1992; 16: 759-763 discussion 763–754
    CrossrefPubMedSuche in Google Scholar
  • 25 Ariton M, Juan CS, AvRuskin TW. Pheochromocytoma: clinical observations from a Brooklyn tertiary hospital. Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2000; 6: 249-252
    CrossrefPubMedSuche in Google Scholar
  • 26 Eisenhofer G, Huynh TT, Elkahloun A et al. Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma. Am J Physiol Endocrinol Metab 2008; 295: E1223-E1233
    CrossrefPubMedSuche in Google Scholar
  • 27 Eisenhofer G, Pacak K, Huynh TT et al. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocrine-related cancer 2011; 18: 97-111
    PubMedSuche in Google Scholar
  • 28 Eisenhofer G, Walther MM, Huynh TT et al Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. The Journal of clinical endocrinology and metabolism 2001; 86: 1999-2008
    CrossrefPubMedSuche in Google Scholar
  • 29 Lenders JW, Duh QY, Eisenhofer G et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. The Journal of clinical endocrinology and metabolism 2014; 99: 1915-1942
    CrossrefPubMedSuche in Google Scholar
  • 30 Barth E, Albuszies G, Baumgart K et al. Glucose metabolism and catecholamines. Crit Care Med 2007; 35: S508-S518
    CrossrefPubMedSuche in Google Scholar
  • 31 Sane CS-Jn T, Raade M. Is biochemical screening for pheochromocytoma in adrenal incidentalomas expressing low unenhanced attenuation on computed tomography necessary?. J Clin Endocrinol Metab 2012; 97: 2077-2083
    CrossrefPubMedSuche in Google Scholar
  • 32 Leung K, Stamm M, Raja A et al. Pheochromocytoma: the range of appearances on ultrasound, CT, MRI, and functional imaging. AJR American journal of roentgenology 2013; 200: 370-378
    CrossrefPubMedSuche in Google Scholar
  • 33 Kim S, Salibi N, Hardie AD et al. Characterization of adrenal pheochromocytoma using respiratory-triggered proton MR spectroscopy: initial experience. AJR American journal of roentgenology 2009; 192: 450-454
    CrossrefPubMedSuche in Google Scholar
  • 34 Muth A, Hammarstedt L, Hellstrom M et al. Cohort study of patients with adrenal lesions discovered incidentally. The British journal of surgery 2011; 98: 1383-1391
    CrossrefPubMedSuche in Google Scholar
  • 35 Mazzaglia PJ. Radiographic evaluation of nonfunctioning adrenal neoplasms. The Surgical clinics of North America 2014; 94: 625-642
    CrossrefPubMedSuche in Google Scholar
  • 36 Mumby C, Davis JR, Trouillas J et al. Phaeochromocytoma and Acromegaly: a unifying diagnosis. Endocrinology, diabetes & metabolism case reports 2014; 2014: 140036
    PubMedSuche in Google Scholar
  • 37 Helck A, Hummel N, Meinel FG et al. Can single-phase dual-energy CT reliably identify adrenal adenomas?. European radiology 2014; 24: 1636-1642
    CrossrefPubMedSuche in Google Scholar